Vanguard Group
AVBP icon

Vanguard Group’s ArriVent BioPharma AVBP Stock Holding History

Vanguard Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$37.6M Sell
1,869,266
-160,265
-8% -$3.34M ﹤0.01% 2318
2025
Q3 		$37.4M Buy
2,029,531
+545,991
+37% +$10.7M ﹤0.01% 2297
2025
Q2 		$32.3M Sell
1,483,540
-19,818
-1% -$412K ﹤0.01% 2328
2025
Q1 		$27.8M Buy
1,503,358
+86,067
+6% +$2.11M ﹤0.01% 2353
2024
Q4 		$37.8M Buy
1,417,291
+71,741
+5% +$2.06M ﹤0.01% 2282
2024
Q3 		$31.6M Buy
1,345,550
+694,476
+107% +$15.8M ﹤0.01% 2381
2024
Q2 		$12.1M Buy
651,074
+2,339
+0.4% +$41.7K ﹤0.01% 2809
2024
Q1 		$11.6M Buy
+648,735
New +$13.1M ﹤0.01% 2867

Other funds holding AVBP

IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Vanguard Group's AVBP Position: Q4 2025 in Review

Vanguard Group reduced its ArriVent BioPharma (AVBP) stake by 7.9% in Q4 2025, selling an estimated $3.34M and leaving 1,869,266 shares worth $37.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2318.

Vanguard Group first reported a position in AVBP in Q1 2024 and has held it in 8 quarters since. The position peaked at $37.8M in Q4 2024. 121 funds tracked by Wall St. Rank hold AVBP as of Q4 2025.

  • Vanguard Group held 1,869,266 shares of ArriVent BioPharma worth $37.6M as of Q4 2025.
  • Vanguard Group sold 160,265 ArriVent BioPharma shares in Q4 2025, an estimated $3.34M.
  • ArriVent BioPharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2318 holding.
  • Vanguard Group first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 8 quarters since.
  • Vanguard Group's ArriVent BioPharma position peaked at $37.8M in Q4 2024.
  • 121 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.